复方血栓通联合激光治疗CSCR的疗效观察

Efficacy of compound Xueshuantong combined laser therapy on central serous chorioretinopathy

摘要:

目的：探讨复方血栓通联合激光治疗中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy，CSCR)的临床疗效。

方法：将我院治疗的181例中心性浆液性脉络膜视网膜病变患者随机分为治疗组91例和对照组90例，对照组行激光治疗，治疗组在激光治疗后口服复方血栓通； 比较两组患者临床疗效、平均光敏感度和血清睾酮、雌激素水平。

结果：治疗后3wk，治疗组总有效率为90.1%，对照组为72.2%，治疗组显著高于对照组(χ²=10.473，P=0.001)； 治疗后6wk，治疗组总有效率亦显著高于对照组(χ²=4.499，P=0.034)。治疗组治愈时间、视力恢复时间均显著少于对照组，平均光敏感度显著高于对照组，两组间相比差异具有统计学意义(P<0.05)。治疗后两组患者相关激素水平均显著降低，其中治疗组血清激素水平降低程度显著优于对照组，组间相比差异具有统计学意义(P<0.05)。

结论：复方血栓通联合激光治疗中心性浆液性脉络膜视网膜病变，能够显著提高疗效，缩短病程，有利于视功能恢复，值得临床推广。

Abstract:

AIM: To explore the clinical therapeutic effect of compound Xueshuantong combined with laser treatment in central serous chorioretinopathy(CSCR)patients.

METHODS: A total of 181 cases of central serous chorioretinopathy patients treated in our hospital were randomly divided into treatment group(91 cases)and control group(90 cases). The patients in control group underwent laser treatment, those in treatment group received oral compound Xueshuantong after laser treatment. Clinical curative effect, the average light sensitivity and serum testosterone, estrogen levels of two group were compared.

RESULTS: After 3wk of treatment, the total effective rate of the treatment group was 90.1%, 72.2% in the control group, the treatment group was significantly higher(χ²=10.473, P=0.001); After 6wk of treatment group, the total effective rate was also significantly higher than that in the control group(χ²=4.499, P=0.034). Healing time, visual recovery time in treatment group was significantly less than those in the control group, the mean sensitivity was significantly higher, the difference between the two groups was statistical significance(P<0.05). After the treatment the hormone of patients in the two groups were significantly decreased, the treatment to reduce the level of serum hormone level was significantly better than those in the control group, the difference between the two groups was statistical significance(P<0.05).

CONCLUSION: Compound Xueshuantong combined with laser in the treatment of central serous chorioretinopathy, can significantly improve the efficacy, shorten the course of disease, is conducive to the recovery of visual function, and worth the clinical promotion.